RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site

RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleot...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature communications 2021-06, Vol.12 (1), p.4045-4045, Article 4045
Hauptverfasser: Haza, Katarzyna Z., Martin, Heather L., Rao, Ajinkya, Turner, Amy L., Saunders, Sophie E., Petersen, Britta, Tiede, Christian, Tipping, Kevin, Tang, Anna A., Ajayi, Modupe, Taylor, Thomas, Harvey, Maia, Fishwick, Keri M., Adams, Thomas L., Gaule, Thembaninkosi G., Trinh, Chi H., Johnson, Matthew, Breeze, Alexander L., Edwards, Thomas A., McPherson, Michael J., Tomlinson, Darren C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signaling pathways with distinct isoform and mutant profiles. Affimer K6 binds in the SI/SII pocket, whilst Affimer K3 is a non-covalent inhibitor of the SII region that reveals a conformer of wild-type RAS with a large, druggable SII/α3 pocket. Competitive NanoBRET between the RAS-binding Affimers and known RAS binding small-molecules demonstrates the potential to use Affimers as tools to identify pharmacophores. This work highlights the potential of using biologics with small interface surfaces to select unseen, druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins. Oncogenic RAS mutants remain difficult to target with small molecules. Here, the authors show that RAS-binding Affimer proteins inhibit RAS signaling while binding diverse regions on the RAS surface, suggesting the potential to use Affimers as tools to identify new binding pockets and pharmacophores.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-021-24316-0